Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 27, 2024 (filed on Mar 27, 2024)Insider Name:Cox JohnOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Cox JohnOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:679,853Price:--
-
Mar 11, 2024 (filed on Mar 13, 2024)Insider Name:High Susanna GattiOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,292Price:$25.70
-
Mar 11, 2024 (filed on Mar 13, 2024)Insider Name:McNeill JonathanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,776Price:$25.71
-
Mar 11, 2024 (filed on Mar 13, 2024)Insider Name:McNeill JonathanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-17,825Price:$25.48
-
Mar 11, 2024 (filed on Mar 13, 2024)Insider Name:McNeill JonathanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:17,825Price:$5.54
-
Mar 11, 2024 (filed on Mar 13, 2024)Insider Name:McNeill JonathanOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-17,825Price:--
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Beskrovnaya OxanaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,081Price:$25.70
-
Mar 08, 2024 (filed on Mar 13, 2024)Insider Name:High Susanna GattiOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-291Price:$27.41
-
Mar 08, 2024 (filed on Mar 13, 2024)Insider Name:High Susanna GattiOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-26,908Price:$26.66
Filings by filing date
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Cox JohnOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:679,853Price:--
-
Mar 27, 2024 (filed on Mar 27, 2024)Insider Name:Cox JohnOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 11, 2024 (filed on Mar 13, 2024)Insider Name:High Susanna GattiOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,292Price:$25.70
-
Mar 08, 2024 (filed on Mar 13, 2024)Insider Name:High Susanna GattiOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-291Price:$27.41
-
Mar 08, 2024 (filed on Mar 13, 2024)Insider Name:High Susanna GattiOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-26,908Price:$26.66
-
Mar 08, 2024 (filed on Mar 13, 2024)Insider Name:McNeill JonathanOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-86,159Price:--
-
Mar 11, 2024 (filed on Mar 13, 2024)Insider Name:McNeill JonathanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,776Price:$25.71
-
Mar 11, 2024 (filed on Mar 13, 2024)Insider Name:McNeill JonathanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-17,825Price:$25.48
-
Mar 11, 2024 (filed on Mar 13, 2024)Insider Name:McNeill JonathanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:17,825Price:$5.54
-
Mar 08, 2024 (filed on Mar 13, 2024)Insider Name:McNeill JonathanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-689Price:$27.31
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1560 Trapelo Road WALTHAM MA 02451 |
Tel: | N/A |
Website: | https://dyne-tx.com |
IR: | See website |
Key People | ||
John Cox President, Chief Executive Officer | Susanna Gatti High Chief Operating Officer | Jonathan McNeill Senior Vice President - Business Development |
Richard Scalzo Senior Vice President, Head of Finance and Administration | Oxana Beskrovnaya Chief Scientific Officer | Wildon Farwell Chief Medical Officer |
Business Overview |
Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases. |
Financial Overview |
For the fiscal year ended 31 December 2023, Dyne Therapeutics Inc revenues was not reported. Net loss increased 40% to $235.9M. Higher net loss reflects Research and de increase of 49% to $159.9M (expense), Labor & Related Expenses in R&D increase of 43% to $39.3M (expense), Stock-based Compensation in R&D increase of 41% to $11.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.23 to -$3.95. |
Employees: | 141 as of Feb 29, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $2,213M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$240.49M as of Dec 31, 2023 |
Net annual income (TTM): | -$235.94M as of Dec 31, 2023 |
Free cash flow (TTM): | -$188.89M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 81,958,068 as of Feb 29, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |